News | November 02, 2025
Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The facility will accommodate over 1,500 employees
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
